公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2015 | Activation of IL6/IGFIR confers poor prognosis of HBV-related hepatocellular carcinoma through induction of OCT4/NANOG expression | Chang T.-S; Wu Y.-C; Chi C.-C; Su W.-C; Chang P.-J; Lee K.-F; Tung T.-H; Wang J; Liu J.-J; Tung S.-Y; Kuo L.-M; HONG-NERNG HO ; THAI-YEN LING ; Huang Y.-H. | Clinical Cancer Research | 82 | 77 | |
2017 | Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study | Ahn M.-J; Kim D.-W; Cho B.C; Kim S.-W; Lee J.S; Ahn J.-S; Kim T.M; CHIA-CHI LIN ; Kim H.R; John T; Kao S; Goldman J.W; Su W.-C; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; CHIH-HSIN YANG | The Lancet Respiratory Medicine | 81 | 67 | |
2016 | Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial | Schuler M; CHIH-HSIN YANG ; Park K; Kim J.-H; Bennouna J; Chen Y.-M; Chouaid C; De Marinis F; Feng J.-F; Grossi F; Kim D.-W; Liu X; Lu S; Strausz J; Vinnyk Y; Wiewrodt R; Zhou C; Wang B; Chand V.K; Planchard D; Bagnes C; Martin C.M; Recondo G; Zarba J.J; Blajman C; Richardet M; McLachlan S.-A; Parente P; Underhill C; Crombie C; Mainwaring P; Greil R; Humblet Y; Bustin F; Carestia L; Galdermans D; Lambrechts M; Delval L; Vercauter P; Zhou C; Wang J; Huang C; Lin X; Wu Y; Liu X; Cheng Y; Qin S; Feng J; Huang J; Zhang Y; Lu S; Zereu M; Garicochea B; Zadra C.A; Riska H; Alanko T; Cadranel J; Chouaid C; Zalcman G; Sibilot D.M; Perol M; Planchard D; Bennouna J; Fournel P; Gervais R; Rotarski M; Coudert B; Thomas M; Wehler T; Faehling M; Keilholz U; Laack E; Von Pawel J; Huber R; Dickgreber N; Wiewrodt R; Mark Z; Tehenes S; Strausz J; Sarosi V; Prabhash K; Jain M; Venkatesan S; Sharma L; Dadhich H; Nagarkar R.V; Onn A; Gottfried M; Stemmer S; Migliorino M.R; Bidoli P; Bearz A; Gridelli C; Milandri C; Platania M; Ceresoli G.L; Cruciani G; Delgado F.G; Perez J.L.G; Luna G.A; Baca O.P; Aerts J; Stigt J; Dingemans A.-M; Herder G; Gans S; Sánchez J.F.S; Barreda R.L.A; Pantigoso W.R; Palomino O.L.M; Jaskiewicz P; Kazarnowicz A; Serwatowski P; Szczesna A; Jassem J; Lubennikov V; Karaseva N; Orlov S; Ragulin Y; Garrido P; Larriba J.L.G; Camps C; Campelo R.G; Lianes P; Cobo M; Felip E; Kim D.-W; Kim S.-W; Park K; Kim J.-H; Han J.-Y; Kim Y.-C; Yang C.-H; Hsia T.-C; Chen Y.-M; Tsai Y.-H; Chang G.-C; Tsao T.C.-Y; Su W.-C; Huang M.-S; Ho C.-L; Hsieh R.-K; Vinnyk Y; Popovych O; Ponomarova O; Bondarenko I; Polishchuk I; Shah R; Mitra S; Popat S; Spicer J; Toy E; Talbot T; Brown E; Upadhyay S; Summers Y; Gurtler J; Meza L; Thropay J; LUX-Lung 5 Investigators | Annals of Oncology | 118 | 110 | |
2015 | Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials | CHIH-HSIN YANG ; Wu Y.-L; Schuler M; Sebastian M; Popat S; Yamamoto N; Zhou C; Hu C.-P; O'Byrne K; Feng J; Lu S; Huang Y; Geater S.L; Lee K.Y; Tsai C.-M; Gorbunova V; Hirsh V; Bennouna J; Orlov S; Mok T; Boyer M; Su W.-C; Lee K.H; Kato T; Massey D; Shahidi M; Zazulina V; Sequist L.V. | The Lancet Oncology | 1318 | 1236 | |
2012 | Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial | Miller V.A; Hirsh V; Cadranel J; Chen Y.-M; Park K; Kim S.-W; Zhou C; Su W.-C; Wang M; Sun Y; Heo D.S; Crino L; Tan E.-H; Chao T.-Y; Shahidi M; Cong X.J; Lorence R.M; CHIH-HSIN YANG | The Lancet Oncology | 879 | 785 | |
2015 | AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer | Jänne P.A; Chih-Hsin CHIH-HSIN YANG ; Kim D.-W; Planchard D; Ohe Y; Ramalingam S.S; Ahn M.-J; Kim S.-W; Su W.-C; Horn L; Haggstrom D; Felip E; Kim J.-H; Frewer P; Cantarini M; Brown K.H; Dickinson P.A; Ghiorghiu S; Ranson M. | New England Journal of Medicine | 1749 | 1621 | |
2021 | Development of a two-dimensional piezoelectric traveling-wave generator | Lin Y.-M; Hsu Y.-H ; Su W.-C; Kao Y.-T; CHIH-KUNG LEE | Journal of Intelligent Material Systems and Structures | | | |
2018 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study | Garassino M.C; Cho B.-C; Kim J.-H; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray J.E; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo R.A; Huang Y; Wadsworth C; Dennis P.A; Rizvi N.A; Paz-Ares Rodriguez L; Novello S; Hiret S; Schmid P; Laack E; Califano R; Maemondo M; Kim S.-W; Chaft J; Vicente Baz D; Berghmans T; Kim D.-W; Surmont V; Reck M; Han J.-Y; Holgado Martin E; Belda Iniesta C; Oe Y; Chella A; Chopra A; Robinet G; Soto Parra H; Thomas M; Cheema P; Katakami N; Su W.-C; Kim Y.-C; Wolf J; Lee J.-S; Saka H; Milella M; Ramos Garcia I; Sibille A; Yokoi T; Kang E.J; Atagi S; Spaeth-Schwalbe E; Nishio M; Imamura F; Gabrail N; Veillon R; Derijcke S; Maeda T; Zylla D; Kubiak K; Santoro A; Uy M.N; Lucien Geater S; Italiano A; Kowalski D; Barlesi F; Chen Y.-M; Spigel D; Chewaskulyong B; Garcia Gomez R; Alvarez Alvarez R; CHIH-HSIN YANG ; Hsia T.-C; Denis F; Sakai H; Vincent M; Goto K; Bosch-Barrera J; Weiss G; Canon J.-L; Scholz C; Aglietta M; Kemmotsu H; Azuma K; Bradbury P; Feld R; Chachoua A; Jassem J; Juergens R; Palmero Sanchez R; Malcolm A; Vrindavanam N; Kubota K; Waller C; Waterhouse D; Coudert B; Mark Z; Satouchi M; Chang G.-C; Herzmann C; Chaudhry A; Giridharan S; Hesketh P; Ikeda N; Boccia R; Iannotti N; Haigentz M; Reynolds J; Querol J; Nakagawa K; Sugawara S; Tan E.H; Hirashima T; Gettinger S; Kato T; Takeda K; Juan Vidal O; Mohn-Staudner A; Panwalkar A; Daniel D; Kobayashi K; Ladrera G.E.I; Schulte C; Sebastian M; Cernovska M; Coupkova H; Havel L; Pauk N; Singh J; Murakami S; Csoszi T; Losonczy G; Price A; Anderson I; Iqbal M; Torri V; Juhasz E; Khanani S; Koubkova L; Levy B; Page R; Bocskei C; Crinò L; Einspahr D; Hagenstad C; Juat N; Overton L; Garrison M; Szalai Z; ATLANTIC Investigators | The Lancet Oncology | 468 | 397 | |
2017 | Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial | Thress K.S; Jacobs V; Angell H.K; CHIH-HSIN YANG ; Sequist L.V; Blackhall F; Su W.-C; Schuler M; Wolf J; Gold K.A; Cantarini M; Barrett J.C; Jänne P.A. | Journal of Thoracic Oncology | 19 | 19 | |
2019 | Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation | CHIH-HSIN YANG ; Gadgeel S.M; Sequist L.V; Wu C.-L; Papadimitrakopoulou V.A; Su W.-C; Fiore J; Saraf S; Raftopoulos H; Patnaik A. | Journal of Thoracic Oncology | 130 | 104 | |
2018 | Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer | Wu Y.-L; Zhang L; Kim D.-W; Liu X; Lee D.H; CHIH-HSIN YANG ; Ahn M.-J; Vansteenkiste J.F; Su W.-C; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan D.S.W. | Journal of Clinical Oncology | 245 | 211 | |
2013 | Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations | Sequist L.V; CHIH-HSIN YANG ; Yamamoto N; O'Byrne K; Hirsh V; Mok T; Geater S.L; Orlov S; Tsai C.-M; Boyer M; Su W.-C; Bennouna J; Kato T; Gorbunova V; Lee K.H; Shah R; Massey D; Zazulina V; Shahidi M; Schuler M. | Journal of Clinical Oncology | 2727 | 2366 | |
2016 | A randomized phase 2 study comparing the combination of ficlatuzumab and gefitinib with gefitinib alone in asian patients with advanced stage pulmonary adenocarcinoma | Mok T.S.K; Geater S.L; Su W.-C; Tan E.-H; CHIH-HSIN YANG ; Chang G.-C; Han M; Komarnitsky P; Payumo F; Garrus J.E; Close S; Park K. | Journal of Thoracic Oncology | 44 | 41 | |
2012 | Ribavirin Enhances the Action of Interferon-α against Hepatitis C Virus by Promoting the p53 Activity through the ERK1/2 Pathway | Liu W.-L.; HUNG-CHIH YANG ; Su W.-C; Wang C.-C; Chen H.-L; HURNG-YI WANG ; Huang W.-H; DING-SHINN CHEN ; Lai M.-Y. | PLoS ONE | 14 | 14 | |